Predicted to enable BMP binding activity; identical protein binding activity; and morphogen activity. Predicted to be involved in several processes, including determination of dorsal identity; negative regulation of BMP signaling pathway; and negative regulation of monocyte chemotaxis. Predicted to act upstream of or within neuron projection morphogenesis and positive regulation of neuron differentiation. Predicted to be located in extracellular region. Predicted to be active in extracellular space. Orthologous to several human genes including MICOS10-NBL1 (MICOS10-NBL1 readthrough); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil; acrylamide.
N03; neuroblastoma 1; neuroblastoma 1, DAN family BMP antagonist; neuroblastoma suppression of tumorigenicity 1; Neuroblastoma suppression of tumorigenicity 1 (DNA segment human D1S1733E); neuroblastoma suppressor of tumorigenicity 1; neuroblastoma, suppression of tumorigenicity 1; Neuroblastoma, suppression of tumorigenicity 1 (DNA segment human D1S1733E); zinc finger protein DAN
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NBL1 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NBL1 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NBL1 mRNA